Latest Breaking News On - Oncology at vanderbilt university medical center - Page 1 : comparemela.com

TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myleoma

Combining talquetamab and daratumumab could create a synergy to get more from talquetamab to attack multiple myeloma.

New orleansUnited statesBhagirathbhair dholariaJordyn savaOncology at vanderbilt university medical centerDepartment of hematologyAmerican society of clinical oncologyJanssen pharmaceuticalsAmerican society of hematologyAmerican societyClinical oncologyVanderbilt university medical centerAmerican journalManaged careBreakthrough therapy

Dr Bhagirathbhai Dholaria Discusses TRiMM-2 Trial Findings

Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.

United statesBhagirathbhair dholariaAmerican society of clinical oncology annual meetingOncology at vanderbilt university medical centerDepartment of hematologyVanderbilt university medical centerClinical oncology annualTrimm 2 trialAsco annual meeting

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the.

United statesTalquetamab monotherapySatu glaweBhagirathbhai dholariaChristie corbettChris heuckMyeloma centerCompanies of johnsonExchange commissionJanssen research developmentOncology at vanderbilt university medical centerReceptor familyc groupNone of the janssen pharmaceutical companiesDivision of hematologyEuropean commissionJanssen biotech inc

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTalquetamab monotherapySatu glaweChristie corbettChris heuckBhagirathbhai dholariaEuropean commissionOncology at vanderbilt university medical centerReceptor familyc groupJanssen biotech incUniversity of arkansasEastern cooperative oncology groupDivision of hematologyExchange commissionMyeloma centerAmerican society of hematology

Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GI

Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.

United statesNew yorkMemorial sloan kettering cancer centerVanderbilt universityKohei shitaraCathy engSteve maronDavidh johnsonAmerican society of clinical oncologyEuropean society of medical oncologyTn vanderbilt ingram cancer center codirectorOncology at vanderbilt university medical centerVanderbilt ingram cancer centerClinical oncologyGastrointestinal cancers symposiumTargeted therapies